title: Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung.
abstract: BACKGROUND
  The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung.
  
  
  METHODS
  A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I.
  
  
  RESULTS
  In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma). Eighty-six tumors showed a presence of SY+ (27%). Univariate analysis showed lower survival rates at 5 years for those patients older than 70 years of age compared with those patients younger than 70 years of age (60.35% vs 70.57%; P = .007) and for those patients with SY+ compared with those with SY- (52.48% vs 72.68%; P = .0017). Patients with SY+ tumors showed a higher rate of recurrence than patients with SY- tumors (50% vs 33.6%; P = .008). Multivariate analysis showed that those patients greater that 70 years of age (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.14-2.65) and the presence of SY (HR, 2.15; 95% CI, 1.40-3.30) were significant independent prognostic factors associated with a poor outcome.
  
  
  CONCLUSIONS
  Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.
authors.affiliation: Thoracic Surgery, Complutense University, Madrid, Spain. fgaragoneses@hotmail.com
authors.forename: Federico
authors.initials: F
authors.lastname: González-Aragoneses
authors.forename: Nicolás
authors.initials: N
authors.lastname: Moreno-Mata
authors.forename: María
authors.initials: M
authors.lastname: Cebollero-Presmanes
authors.forename: Mariano
authors.initials: M
authors.lastname: García-Yuste
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Cañizares-Carretero
authors.forename: Laureano
authors.initials: L
authors.lastname: Molins-López-Rodó
authors.forename: Santiago
authors.initials: S
authors.lastname: Quevedo-Losada
authors.forename: Juan
authors.initials: J
authors.lastname: Torres-Lanzas
authors.forename: Emilio
authors.initials: E
authors.lastname: Alvarez-Fernández
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016708:Synaptophysin / Q000378:metabolism*
chemical_list: D016708:Synaptophysin